Antibody-Armed Platelets for the Regenerative Targeting of Endogenous Stem Cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30775924.
- Also identified by DOI 10.1021/acs.nanolett.8b04970 and PMC identifier 7025326.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Stem cell therapies have shown promise in treating acute and chronic ischemic heart disease. However, current therapies are limited by the low retention and poor integration of injected cells in the injured tissue. Taking advantage of the natural infarct-homing ability of platelets, we engineered CD34 antibody-linked platelets (P-CD34) to capture circulating CD34-positive endogenous stem cells and direct them to the injured heart. In vitro, P-CD34 could bind to damaged aortas and capture endogenous stem cells in whole blood. In a mouse model of acute myocardial infarction, P-CD34 accumulated in the injured heart after intravenous administration, leading to a concentration of endogenous CD34 stem cells in the injured heart for effective heart repair. This represents a new technology for endogenous stem cell therapy.
Medical subject headings
- Antigens, CD34
- Blood Platelets
- Cell- and Tissue-Based Therapy
- Heart Injuries
- Myocardial Infarction